Company News-Novamab

Our Story

Share the latest information

Our Story

News

Good news! Novamab has been listed on the 2024 Cyzone 100 Future Unicorn List

On December 19th, the grand opening of the 2024 Cyzone 100 Future Unicorn Conference and Cyzone Annual Meeting, themed 'Crossing the Alps - Boundless Travelers', took place in Chengdu. N

Good news! Novamab has been listed on the 2024 Cyzone 100 Future Unicorn List

On December 19th, the grand opening of the 2024 Cyzone 100 Future Unicorn Conference and Cyzone Annual Meeting, themed 'Crossing the Alps - Boundless Travelers', took place in Chengdu. N

Congratulations to Dr. Wan Yakun, founder of Novamab for being selected as the "Pearl Leading Talent" for Pudong New Area in 2024

On December 7, 2024, the 2024 Pudong International Talent Port Forum was held at the Zhangjiang Science Hall. The forum officially unveiled and honored the recipients of the 'Pearl Plan' for P

Good news! Novamab Ranks in the Top 10 Most Promising Biopharma Companies on the Huayi List 2024

From September 8th to September 10th, the Huayi List · 2024 China Biomedical Technology Innovation Value List, jointly initiated by Yiyun Technology and the National Technology Transfer Eastern Center

Novamab, the world's first inhaled nanobodycompany, officially announced the completion of nearly 300 million RMB in Series B financing

Shanghai, China, July 31, 2024- Shanghai Novamab Biopharmaceuticals Co., Ltd. (the "Company" or "Novamab"), a biotechnology company dedicated to the research and development of innovative nanobody drugs, officially announced the completion of its Series B2 financing of nearly 200 millionRMB, which was led by Qiming Venture Capital, with participation of Huangpu Biopharmaceutical Fund and Jiuyu Investment.

International Conference 及2024 BIO International Convention

Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun

Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical Study
— The First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients

Shanghai, China, April 23, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced that its core product LQ036 (an IL-4Rα single-domain

BioCon 2024- "Research Progress of Inhalable Nanobody Drug Therapy for Asthma" A Brief Discussion on Differentiated Development of Antibody Drugs and Clinical Progress of Novamab

Beijing time, March 6, 2024 (Wednesday), from 19:45 to 20:25, Dr. Siran Pei, the head of Translational Medicine and Clinical Development at Novamab, will participate in the pre-event live broadcast of

Research Information - The development and scaling up of the production process of Novamab‘s anti TSLP Nanobody have reached an internationally leading level

Shanghai, February 29, 2024 - Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced the research progress on the development and scaling up

Clinical Research Updatate - Novamab Announced the Latest Results of the Phase Ia Clinical Study on Inhaled TSLP Nanobody Drug LQ043H in Healthy Chinese Subjects

Shanghai, February 22, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nonobody drugs, announced today the results of the tolerance, safety, pharmacokine

Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan

On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.

总计 55 12 3 4 5 6